Article - BioPharm International

ADVERTISEMENT

Article

Biotech Manufacturers Face Competition from "Similar" Follow-Ons

August 1, 2007

The main testing and regulatory provisions of the FOB legislation reflect multiple trade-offs between the demands of innovators and generics firms.

From the Editor: After Zheng

August 1, 2007

The corruption of China's food and drug sectors is not limited to one man. Likewise, real reform will require the efforts of many.

Patents: Patent Strategies for Biotechnology Enterprises

August 1, 2007

Companies in the biotech industry typically require one or several partners as they complete the product development cycle.

Outsourcing: Managing Your Contractor Relationship—A Smart Investment

August 1, 2007

Companies need to avoid operating in a manner that is inconsistent with the priorities established in the strategic sourcing decision.

Drug Delivery: What The Future Holds

August 1, 2007

Drug delivery technologies have the potential to enable drug candidates with poor pharmaceutical or biopharmaceutical properties, both for macromolecule and traditional compounds. While there have been many success stories to date, the future offers even more promise. In this article, the author surveys the top ten areas in drug delivery looking forward.

China Today: Biopharmaceutical Exports

August 1, 2007

In 2006, China exported a total of $890 million in biologics to other countries—a 30.61% increase, compared with the previous year.

Outsourcing Insights: Why European CMOs Are Coming to America

July 1, 2007

The BIO annual meeting in early May had an upbeat tone. Investment capital is flowing into the industry at high levels, resulting in strong demand for contract development services. The funding stream is particularly strong in the US, and that is attracting more European contract manufacturers (CMOs) eager to improve business development here.

Street Talk: Cautious Optimism: the Watchwords for Volatile Sector

July 1, 2007

We're seeing an uptick in biotech investing from the venture capital community, a good sign that biotech can rise even higher than the broader markets.

Upstream Processing: Regulatory Considerations Regarding Quality Aspects of Monoclonal Antibodies

July 1, 2007

ADVERTISEMENT

ADVERTISEMENT

Click here